Lilly posts pro forma on ImClone deal

Eli Lilly expects its combination with ImClone to deliver $15.5 billion in revenues for the nine months ended Sept. 30 and a combined EPS of 1.21, which because of acquisition costs and interest expenses is some 20 cents per share less than Lilly would have produced on its own. Report

Suggested Articles

Pharma

How life sciences brands can win on mobile, right now

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Sponsored by Rebecca Willumson
shkreli
Pharma

Supreme Court refuses to take up Shkreli's conviction appeal

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

by Kyle Blankenship
OxyContin
Pharma

How Purdue planted the opioid 'anti-story'

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.

by David Armstrong, ProPublica